Depression treatment for Boca Raton — the full escalation pathway, 20 minutes away.

RECO Integrated Psychiatry runs an outpatient specialty psychiatry practice 20 minutes north of Boca Raton in Delray Beach, structured around measurement-based depression care rather than refill-cycle prescribing. Clients from Mizner Park, Downtown Boca, and Boca West receive a documented DSM-5-TR diagnosis, PHQ-9-tracked medication trials at adequate dose and duration, and a named interventional pathway — TMS, Spravato, or IV ketamine — activated at the second failed trial rather than the fifth.

From Mizner Park or Royal Palm Place, RECO Integrated Psychiatry’s Delray Beach office is roughly 20 minutes up Federal Highway — an 11-mile drive that fits into the schedule most Boca Raton adults already keep. That distance matters because outpatient depression care done correctly requires consistent appointments over months rather than a single evaluation followed by a refill queue. For Boca Raton residents who have cycled through primary-care antidepressants without full remission, a psychiatry-led treatment plan built on structured measurement and a defined escalation pathway is the difference between another partial response and actual recovery.

The diagnostic questions primary care doesn’t ask

Before any medication change is made, RECO’s psychiatrists work through the differential that ten-minute primary-care visits rarely have room for. Unrecognized bipolar spectrum illness is the single most common misdiagnosis behind so-called treatment-resistant presentations — antidepressant monotherapy in bipolar II or bipolar spectrum disorders can induce mixed states, rapid cycling, and paradoxical worsening of mood instability. The MDQ, the HCL-32, and a structured mood history that specifically probes for hypomania, family psychiatric history, and antidepressant-induced activation are completed at intake, not after the third failed SSRI.

Beyond bipolarity, the initial evaluation screens for the conditions that routinely masquerade as major depression. Undertreated OCD scored on the Y-BOCS, PTSD with predominant anhedonia, adult ADHD screened with the ASRS, chronic sleep-disordered breathing, and subclinical hypothyroidism all present with the same PHQ-9 elevation and the same subjective flatness — but each requires the underlying condition to be treated rather than another antidepressant layered on top. Substance use, particularly alcohol, cannabis, and stimulant misuse, is quantified against ASAM Criteria dimensions before the pharmacology is considered, because active substance use lowers response rates across every antidepressant class.

The point of the workup is not thoroughness for its own sake. Most depression referred as treatment-resistant is undiagnosed comorbidity or misdiagnosis caught late — and catching it at intake instead of at trial four saves months of the wrong treatment.

First-line pharmacotherapy done well

When the diagnosis is confirmed major depressive disorder, first-line pharmacotherapy means an SSRI or SNRI started at a starting dose, titrated to therapeutic dose within two to four weeks, and given a full six-to-eight-week trial before response is judged. Sertraline, escitalopram, and fluoxetine are the SSRI defaults; venlafaxine XR and duloxetine are the SNRI options when comorbid anxiety, chronic pain, or fatigue prominence is present. Bupropion is chosen when sexual side effects, weight gain, or excessive sedation would compromise adherence — its noradrenergic and dopaminergic profile also makes it a reasonable pick for depression with prominent anergia or executive dysfunction.

Mirtazapine has a specific role for insomnia-predominant depression with poor appetite; its histaminergic and 5-HT2 profile addresses both symptom clusters in a single agent. For clients with prominent anxious distress or a mixed-features specifier, low-dose adjunctive quetiapine carries stronger evidence than pure serotonergic monotherapy. Buspirone is available for residual generalized anxiety after the primary agent stabilizes mood.

The unglamorous requirement — and the one most scattered treatment histories fail — is documentation of adequate dose and adequate duration for each trial. Insurance coverage for TMS, Spravato, and other interventional treatments depends on evidence of two failed adequate trials, and adequate has a specific definition. RECO documents dose, duration, PHQ-9 change, side-effect profile, and the reason each medication was discontinued — the record that makes later escalation possible.

Augmentation and switching after partial response

Partial responders — clients whose PHQ-9 has dropped meaningfully but not into remission — are augmented before they are switched. This is where evidence-based sequencing diverges most sharply from typical outpatient practice, which tends to abandon partially working medications and start over. The augmentation options with the strongest evidence are aripiprazole at 2 to 15 mg (typically effective at lower doses than in psychosis), lithium targeting a serum level of 0.4 to 0.8 mEq/L for augmentation, and thyroid supplementation with T3 at 25 to 50 mcg. Bupropion augmentation of an SSRI addresses residual anergia and can partially offset SSRI-related sexual dysfunction. Olanzapine-fluoxetine combination is available for depression with psychotic features.

For frank non-responders — no meaningful PHQ-9 movement after an adequate trial — a within-class switch has limited supporting evidence. Cross-class switches to an SNRI, to bupropion, or to mirtazapine outperform within-class swaps in the STAR*D data and subsequent meta-analyses. When switching, cross-titration is planned to avoid discontinuation symptoms and to keep the client covered during the transition.

Structured psychotherapy is integrated at this stage, not deferred. CBT for depression, behavioral activation for anhedonic presentations, ACT for clients with prominent avoidance, and motivational interviewing for adherence work run alongside the pharmacology — the combined-treatment response rate exceeds either modality alone at every severity level.

The interventional escalation pathway

Two adequate antidepressant trials without remission meets the definition of treatment-resistant depression and opens coverage for interventional options. RECO’s protocol names the escalation pathway at the second failed trial rather than the fourth or fifth — the delay to interventional treatment is one of the most consistent gaps in community psychiatric care and one of the strongest predictors of chronic disability from depression.

Repetitive TMS delivers 3000 pulses per session at 120% of the individually measured motor threshold to the left dorsolateral prefrontal cortex, five days per week for four to six weeks. It is non-sedating; clients drive themselves to sessions and return to work the same day. Spravato (esketamine) is delivered under REMS-monitored dosing for clients who need a rapid-response option and meet the specific coverage criteria. IV ketamine is available as a cash-pay option for clients whose insurance will not cover Spravato or who need a compressed dosing schedule.

The choice among TMS, Spravato, and IV ketamine is made against clinical factors — cardiovascular history, dissociative tolerance, seizure risk, work and childcare logistics — rather than by whichever intervention the clinic happens to offer. This is what an escalation pathway means: named, sequenced, and matched to the clinical picture.

What to expect at the first visit

The initial psychiatric evaluation runs 60 to 90 minutes. It includes a structured DSM-5-TR diagnostic interview, PHQ-9 and GAD-7 scored at baseline, MDQ and PTSD screening, a full medication and prior-trial history, and — when clinically indicated — a lab panel for thyroid function, vitamin D, B12, and metabolic markers. Prior treatment records are requested in advance so the visit can be spent on clinical decision-making rather than history reconstruction.

By the end of the first visit, the client leaves with a documented diagnosis, a written treatment plan, a specific medication decision with dose and titration schedule, and a follow-up interval. Follow-up during the first two months is typically every two to three weeks — the interval at which dose adjustments and side-effect management actually happen — before spacing out as remission is achieved and maintained.

Insurance and admissions from Boca Raton

RECO Integrated Psychiatry participates with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS PPO plans for outpatient psychiatric services. Verification of benefits for the initial evaluation, medication management follow-ups, and — where relevant — TMS or Spravato coverage is completed before the first appointment. For Boca Raton residents, the practical logistics are straightforward: the Delray Beach office sits 11 miles up Federal Highway or I-95, and most clients from Mizner Park, Royal Palm Place, Downtown Boca, Boca West, and Highland Beach arrive in 20 minutes or less outside of rush hour.

Comprehensive outpatient depression treatment under commercial insurance typically covers the full first-line and second-line pathway, with additional prior authorization for TMS and Spravato once treatment-resistant criteria are met and documented.

Serving residents of: Mizner Park, Royal Palm Place, Downtown Boca, Boca West, Highland Beach.